US FDA Tried, But Failed, To Take Compounding Issue Off The Table At Makena AdComm

 
• By Sue Sutter
  
Mortar
Withdrawal of Makena will drive clinicians and patients to seek out compounded versions of 17P, panelists said. • Source: Shutterstock
Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

SpotifyApple PodcastsWebsite

More from US FDA Performance Tracker

More from Regulatory Trackers